English

→ كل الأعضاء · الأصوات الرئيسية

H.R. 2821 · 119th Congress

FDA Modernization Act 3.0

عدّى مجلس النوابالصحة

البيانات

قدّمه
بادي كارتر (R)
تاريخ التقديم
2025-04-10
مجلس المنشأ
مجلس النواب
المجال
Health
آخر إجراء
2026-07-21 — Received in the Senate.
المشاركين في الرعاية
41

congress.gov

الملخص

FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.

CRS summary — Introduced in House (2025-04-10)